Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
319 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Malignant Pleural Mesothelioma - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Malignant Pleural Mesothelioma - Pipeline Review, H1 2016', provides an overview of the Malignant Pleural Mesothelioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Pleural Mesothelioma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma - The report reviews pipeline therapeutics for Malignant Pleural Mesothelioma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Malignant Pleural Mesothelioma therapeutics and enlists all their major and minor projects - The report assesses Malignant Pleural Mesothelioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Malignant Pleural Mesothelioma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Mesothelioma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Malignant Pleural Mesothelioma Overview 8 Therapeutics Development 9 Pipeline Products for Malignant Pleural Mesothelioma - Overview 9 Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis 10 Malignant Pleural Mesothelioma - Therapeutics under Development by Companies 11 Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes 13 Malignant Pleural Mesothelioma - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Malignant Pleural Mesothelioma - Products under Development by Companies 17 Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes 20 Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development 21 Aduro BioTech, Inc. 21 Advantagene, Inc. 22 Amphera BV 23 AnGes MG, Inc. 24 ArQule, Inc. 25 Bayer AG 26 Biogen, Inc. 27 Bionomics Limited 28 Biotecnol, Inc. 29 Boehringer Ingelheim GmbH 30 Boston Biomedical, Inc. 31 Bristol-Myers Squibb Company 32 CanBas Co., Ltd. 33 Concordia Healthcare Corp. 34 Eli Lilly and Company 35 EnGeneIC Ltd 36 F. Hoffmann-La Roche Ltd. 37 Five Prime Therapeutics, Inc. 38 Genelux Corporation 39 GlaxoSmithKline Plc 40 Juno Therapeutics Inc. 41 Merck & Co., Inc. 42 Millennium Pharmaceuticals, Inc. 43 MolMed S.p.A. 44 Morphotek, Inc. 45 Novartis AG 46 Ono Pharmaceutical Co., Ltd. 47 Oxford BioMedica Plc 48 Pfizer Inc. 49 Pharma Mar, S.A. 50 Polaris Pharmaceuticals, Inc. 51 Sellas Inc. 52 Synta Pharmaceuticals Corp. 53 VasGene Therapeutics, Inc. 54 Verastem, Inc. 55 Virttu Biologics Limited 56 Vyriad 57 Malignant Pleural Mesothelioma - Therapeutics Assessment 58 Assessment by Monotherapy Products 58 Assessment by Target 59 Assessment by Mechanism of Action 62 Assessment by Route of Administration 65 Assessment by Molecule Type 67 Drug Profiles 69 Ad5-SGE-REIC/Dkk3 - Drug Profile 69 alisertib - Drug Profile 71 amatuximab - Drug Profile 76 anetumab ravtansine - Drug Profile 79 ascrinvacumab - Drug Profile 81 bevacizumab - Drug Profile 82 BG-00001 - Drug Profile 89 BMS-986148 - Drug Profile 90 BNC-105 - Drug Profile 91 CBP-501 - Drug Profile 94 Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile 96 Cellular Immunotherapy for Oncology and Infectious Disease - Drug Profile 97 CRS-207 - Drug Profile 98 CSG-MESO - Drug Profile 101 defactinib hydrochloride - Drug Profile 102 FP-1039 - Drug Profile 104 galinpepimut-S - Drug Profile 106 ganetespib - Drug Profile 108 GEN-0101 - Drug Profile 113 Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile 115 Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile 116 GLONC-1 - Drug Profile 117 GSK-2256098 - Drug Profile 120 HSV-1716 - Drug Profile 122 iCasp9M28z - Drug Profile 125 JTCR-016 - Drug Profile 126 LY-3023414 - Drug Profile 127 MesoCancerVac - Drug Profile 129 MesoCART - Drug Profile 130 Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 131 napabucasin - Drug Profile 133 NGR-hTNF - Drug Profile 136 nintedanib - Drug Profile 140 nivolumab - Drug Profile 145 Oncolytic Virus to Target CD46 for Malignant Pleural Mesothelioma - Drug Profile 153 OXB-301 - Drug Profile 154 pegargiminase - Drug Profile 157 pembrolizumab - Drug Profile 161 porfimer sodium - Drug Profile 172 rAd-IFN - Drug Profile 174 S-588210 - Drug Profile 176 Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile 177 TargomiRs - Drug Profile 178 Tb-535 - Drug Profile 180 tivantinib - Drug Profile 181 trabectedin - Drug Profile 184 Vas-01 - Drug Profile 190 VS-5584 - Drug Profile 192 Malignant Pleural Mesothelioma - Recent Pipeline Updates 194 Malignant Pleural Mesothelioma - Dormant Projects 302 Malignant Pleural Mesothelioma - Discontinued Products 303 Malignant Pleural Mesothelioma - Product Development Milestones 304 Featured News & Press Releases 304 Appendix 314 Methodology 314 Coverage 314 Secondary Research 314 Primary Research 314 Expert Panel Validation 314 Contact Us 314 Disclaimer 315
List of Tables
Number of Products under Development for Malignant Pleural Mesothelioma, H1 2016 13 Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Development, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Development by Companies, H1 2016 (Contd..2) 23 Products under Investigation by Universities/Institutes, H1 2016 24 Malignant Pleural Mesothelioma - Pipeline by Aduro BioTech, Inc., H1 2016 25 Malignant Pleural Mesothelioma - Pipeline by Advantagene, Inc., H1 2016 26 Malignant Pleural Mesothelioma - Pipeline by Amphera BV, H1 2016 27 Malignant Pleural Mesothelioma - Pipeline by AnGes MG, Inc., H1 2016 28 Malignant Pleural Mesothelioma - Pipeline by ArQule, Inc., H1 2016 29 Malignant Pleural Mesothelioma - Pipeline by Bayer AG, H1 2016 30 Malignant Pleural Mesothelioma - Pipeline by Biogen, Inc., H1 2016 31 Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H1 2016 32 Malignant Pleural Mesothelioma - Pipeline by Biotecnol, Inc., H1 2016 33 Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 34 Malignant Pleural Mesothelioma - Pipeline by Boston Biomedical, Inc., H1 2016 35 Malignant Pleural Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H1 2016 36 Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H1 2016 37 Malignant Pleural Mesothelioma - Pipeline by Concordia Healthcare Corp., H1 2016 38 Malignant Pleural Mesothelioma - Pipeline by Eli Lilly and Company, H1 2016 39 Malignant Pleural Mesothelioma - Pipeline by EnGeneIC Ltd, H1 2016 40 Malignant Pleural Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 41 Malignant Pleural Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H1 2016 42 Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H1 2016 43 Malignant Pleural Mesothelioma - Pipeline by GlaxoSmithKline Plc, H1 2016 44 Malignant Pleural Mesothelioma - Pipeline by Juno Therapeutics Inc., H1 2016 45 Malignant Pleural Mesothelioma - Pipeline by Merck & Co., Inc., H1 2016 46 Malignant Pleural Mesothelioma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 47 Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H1 2016 48 Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H1 2016 49 Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H1 2016 50 Malignant Pleural Mesothelioma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 51 Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica Plc, H1 2016 52 Malignant Pleural Mesothelioma - Pipeline by Pfizer Inc., H1 2016 53 Malignant Pleural Mesothelioma - Pipeline by Pharma Mar, S.A., H1 2016 54 Malignant Pleural Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 55 Malignant Pleural Mesothelioma - Pipeline by Sellas Inc., H1 2016 56 Malignant Pleural Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H1 2016 57 Malignant Pleural Mesothelioma - Pipeline by VasGene Therapeutics, Inc., H1 2016 58 Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H1 2016 59 Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited, H1 2016 60 Malignant Pleural Mesothelioma - Pipeline by Vyriad, H1 2016 61 Assessment by Monotherapy Products, H1 2016 62 Number of Products by Stage and Target, H1 2016 64 Number of Products by Stage and Mechanism of Action, H1 2016 67 Number of Products by Stage and Route of Administration, H1 2016 70 Number of Products by Stage and Molecule Type, H1 2016 72 Malignant Pleural Mesothelioma Therapeutics - Recent Pipeline Updates, H1 2016 198 Malignant Pleural Mesothelioma - Dormant Projects, H1 2016 306 Malignant Pleural Mesothelioma - Discontinued Products, H1 2016 307
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
